Benefits Semaglutide and liraglutide share a few common benefits, such as: Both drugs promote blood sugar control in patients with type 2 diabetes Semaglutide (Wegovy) and liraglutide (Saxenda) help reduce body weight in obese and overweight patients Both drugs have potential cardiovascular benefits and reduce the risk of heart attack, stroke, and cardiovascular death Side effects As semaglutide and liraglutide belong to the same class of drugs (GLP-1 receptor agonist), they have common side effects such as nausea, vomiting, diarrhea, constipation, stomach pain, injection site reaction, and pancreatitis
It is not the medication damaging the mouth directly, but the secondary effects." Finally: "If dry mouth becomes persistent, severe, or affects sleep or eating, it is sensible to speak with a doctor, pharmacist, or dentist
laboratory analytical applications Research Focus (Non-clinical): Peptide interaction and receptor pathway investigations Research involving signaling response mechanisms Compound integrity and stability analysis Controlled laboratory evaluation of peptide formulations Advanced analytical and biochemical research applications Notes for Investigators: Tirzepatide is supplied for qualified laboratory research purposes only
Common side effects in Week 1 The most commonly reported side effects during the first week include mild nausea, reduced appetite, constipation, diarrhoea, stomach cramps, bloating, and headaches
These results support a favorable benefitrisk profile of semaglutide 7.2 mg for weight management in people with obesity, wrote the authors